Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Overview of ALK and ROS1 Rearranged Lung Cancer

  • Choi, Chang Min (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2013.06.19
  • Accepted : 2013.07.03
  • Published : 2013.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Many attempts have been made to find genetic abnormalities inducing carcinogenesis after the development of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor targeting EGFR in lung cancer. New target therapies have been already commercialized and studied along with the recent discovery of gene rearrangement involved in the carcinogenic process of non-small cell lung cancer. This study aims to investigate anplastic lymphoma kinase, c-ros oncogene 1, and receptor tyrosine kinase, in particular.

Keywords

References

  1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. https://doi.org/10.1038/nature05945
  2. Doebele RC, Camidge DR. Targeting ALK, ROS1, and BRAF kinases. J Thorac Oncol 2012;7(16 Suppl 5):S375-6. https://doi.org/10.1097/JTO.0b013e31826df05e
  3. Paik JH, Choi CM, Kim H, Jang SJ, Choe G, Kim DK, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9. https://doi.org/10.1016/j.lungcan.2011.11.008
  4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in nonsmall- cell lung cancer. N Engl J Med 2010;363:1693-703. https://doi.org/10.1056/NEJMoa1006448
  5. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363:1734-9. https://doi.org/10.1056/NEJMoa1007478

Cited by

  1. Chromosomal rearrangements in cancer : Detection and potential causal mechanisms vol.1, pp.1, 2014, https://doi.org/10.4161/mco.29904
  2. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK vol.57, pp.4, 2013, https://doi.org/10.1021/acs.jcim.7b00019